FierceBiotech4d
Novartis pays China's Baiyu $70M upfront, with $1.1B chaser, for small molecule cancer candidate
Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...
The Pharma Letter4d
Chengdu Baiyu enters into a license deal with Novartis
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma ...
PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug
European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data ...
Yahoo Finance4d
BAIYU Holdings, Inc. (BYU)
BAIYU Holdings, Inc. (Nasdaq: BYU) (the "Company" or "BAIYU"), a leading B2B bulk commodity e-commerce platform and supply chain service provider, today announced that it has filed timely a formal ...
FiercePharma3d
Fierce Pharma Asia—Lilly's China expansions; Gilead's scrapped MASH deal; Leqembi's vial scrutiny
Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...
Morningstar4d
Baiyu Holdings Inc BYU
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
PipelineReview.com4d
Chengdu Baiyu enters into a license agreement for the development and commercialization of its Anti-tumor small molecule inhibitor
CHENGDU, China I October16, 2024 I Chengdu Baiyu Pharmaceutical Co., Ltd. ("Baiyu") today announced that it has entered into an exclusive license ...
ENDPOINTS NEWS4d
No­var­tis pays $70M up­front to li­cense Chi­nese biotech’s an­ti­tu­mor drug
Novartis is spending $70 million upfront on a small molecule antitumor drug from the Chinese biotech Chengdu Baiyu. The Swiss ...